advertisement
14 Costing studies; pharmacoeconomics (6)
Showing records 1 to 6
Display all abstracts in classification 14 Costing studies; pharmacoeconomics
Search within classification 14 Costing studies; pharmacoeconomics13582 Estimated comparative costs of achieving a 20% reduction in intraocular pressure with bimatoprost or latanoprost in patients with glaucoma or ocular hypertension
Fiscella R; Walt J
Drugs and Aging 2006; 23: 39-47
13720 Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications
Goldberg LD; Walt J
PharmacoEconomics 2006; 24: 251-264
13940 Update on utilities and cost-utility analyses
Hollands H; Sharma S
Current Opinions in Ophthalmology 2006; 17: 223-227
13938 Cost-effectiveness analysis in glaucoma: what drives utility? Results from a pilot study in Sweden
Kobelt G; Jonsson B; Bergstrom A; Chen E; Linden C; Alm A
Acta Ophthalmologica Scandinavica 2006; 84: 363-371
13939 Management of ocular hypertension: A cost-effectiveness approach from the Ocular Hypertension Treatment Study
Kymes SM; Kass MA; Anderson DR; Miller JP; Gordon MO; Ocular Hypertension Treatment Study Group (OHTS)
American Journal of Ophthalmology 2006; 141: 997-1008
13651 Evaluation of non-medical costs associated with visual impairment in four European countries: France, Italy, Germany and the UK
Lafuma A; Brezin A; Lopatriello S; Hieke K; Hutchinson J; Mimaud V; Berdeaux G
PharmacoEconomics 2006; 24: 193-205
